115 related articles for article (PubMed ID: 8272148)
1. Evaluation of 2-(methylaminosulfonyl)-1-(arylsulfonyl)-1-methylhydrazines as anticancer agents.
Sanyal U; De R; Dutta S; Das H; Ghost M
Neoplasma; 1993; 40(4):219-22. PubMed ID: 8272148
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of 2-(methylaminosulfonyl)-1-(arylsulfonyl)hydrazines as anticancer agents.
Ghosh M; Dutta S; Sanyal U
Neoplasma; 1999; 46(4):242-5. PubMed ID: 10613605
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the anticancer property of a new alpha-methylene-gamma-lactone derivative of phthalimide.
Sanyal U; Dutta S; Das H
Neoplasma; 1995; 42(3):129-32. PubMed ID: 7637822
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and evaluation of ethylnitrosoureas of substituted naphthalimides as anticancer compounds.
Pain A; Samanta S; Dutta S; Saxena AK; Shanmugavel M; Sharma M; Qazi GN; Sanyal U
Acta Pol Pharm; 2007; 64(1):27-33. PubMed ID: 17665847
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of fluorenhymustine as a rationally designed novel anticancer agent.
Samanta S; Pain A; Ghosh M; Dutta S; Sanyal U
Exp Oncol; 2005 Dec; 27(4):279-85. PubMed ID: 16404347
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of naphthal-NU, a 2-chloroethylnitrosourea derivative of naphthalimide, as a mixed-function anticancer agent.
Samanta S; Pain A; Dutta S; Sanyal U
J Exp Clin Cancer Res; 2002 Mar; 21(1):87-93. PubMed ID: 12071535
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and evaluation of 2-chloroethylnitrosoureas of substituted naphthalimides as mixed-function anticancer compounds.
Samanta S; Pain A; Dutta S; Sanyal U
Acta Pol Pharm; 2001; 58(5):351-6. PubMed ID: 11876442
[TBL] [Abstract][Full Text] [Related]
8. Alkylphosphonium salts as a new class of antitumor agents.
Sanyal U; Chatterjee RS; Das SK; Chakraborti SK
Neoplasma; 1984; 31(2):149-55. PubMed ID: 6717684
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of imidazothioxanthones in murine and human tumor models in vitro and in vivo.
Varvaresou A; Iakovou K; Gikas E; Fichtner I; Fiebig HH; Kelland LR; Double JA; Bibby MC; Hendriks HR
Anticancer Res; 2004; 24(2B):907-19. PubMed ID: 15161044
[TBL] [Abstract][Full Text] [Related]
10. Novel modified steroid derivatives of androstanolone as chemotherapeutic anti-cancer agents.
El-Far M; Elmegeed GA; Eskander EF; Rady HM; Tantawy MA
Eur J Med Chem; 2009 Oct; 44(10):3936-46. PubMed ID: 19447526
[TBL] [Abstract][Full Text] [Related]
11. Potent antitumor activity of a novel nucleoside analogue, BCH-4556 (beta-L-dioxolane-cytidine), in human renal cell carcinoma xenograft tumor models.
Kadhim SA; Bowlin TL; Waud WR; Angers EG; Bibeau L; DeMuys JM; Bednarski K; Cimpoia A; Attardo G
Cancer Res; 1997 Nov; 57(21):4803-10. PubMed ID: 9354442
[TBL] [Abstract][Full Text] [Related]
12. The primary in vitro anticancer activity of "half-mustard type" phenothiazines in NCI's revised anticancer screening paradigm.
Wuonola MA; Palfreyman MG; Motohashi N; Kawase M; Gabay S; Gupta RR; Molnár J
Anticancer Res; 1998; 18(1A):337-48. PubMed ID: 9568100
[TBL] [Abstract][Full Text] [Related]
13. Synthesis of S-dialkylarsino-3-mercapto-1,2-propanediols and evaluation of their anticancer activity.
Gao M; Tan S; Chen Y; Zingaro RA
Bioorg Med Chem; 2007 Apr; 15(7):2660-6. PubMed ID: 17287125
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and evaluation of substituted naphthalimide nitrogen mustards as rationally designed anticancer compounds.
Pain A; Samanta S; Dutta S; Saxena AK; Shanmugavel M; Kampasi H; Quazi GN; Sanyal U
Acta Pol Pharm; 2003; 60(4):285-91. PubMed ID: 14714857
[TBL] [Abstract][Full Text] [Related]
15. New arylsulfonylhydrazones of substituted benzaldehydes as anticancer agents.
Pal P; Sanyal U; Chakraborti SK
Neoplasma; 1983; 30(5):551-6. PubMed ID: 6656958
[TBL] [Abstract][Full Text] [Related]
16. A novel class of achiral seco-analogs of CC-1065 and the duocarmycins: design, synthesis, DNA binding, and anticancer properties.
Kupchinsky S; Centioni S; Howard T; Trzupek J; Roller S; Carnahan V; Townes H; Purnell B; Price C; Handl H; Summerville K; Johnson K; Toth J; Hudson S; Kiakos K; Hartley JA; Lee M
Bioorg Med Chem; 2004 Dec; 12(23):6221-36. PubMed ID: 15519165
[TBL] [Abstract][Full Text] [Related]
17. Antitumor actions of imidazolyl-(4-oxoquinazolin-3(4H)-yl)-acetamides against Ehrlich Ascites Carcinoma.
Raghavendra NM; Gurubasavarajaswamy PM; Nagaranavile KS; Parameshwaran T
Arch Pharm Res; 2009 Mar; 32(3):431-6. PubMed ID: 19387588
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and in vitro evaluation of the anticancer activity of novel fluorinated thiazolo[4, 5-d]pyrimidines.
Fahmy HT; Rostom SA; Saudi MN; Zjawiony JK; Robins DJ
Arch Pharm (Weinheim); 2003 Jul; 336(4-5):216-25. PubMed ID: 12916055
[TBL] [Abstract][Full Text] [Related]
19. Identification of non-cross-resistant platinum compounds with novel cytotoxicity profiles using the NCI anticancer drug screen and clustered image map visualizations.
Fojo T; Farrell N; Ortuzar W; Tanimura H; Weinstein J; Myers TG
Crit Rev Oncol Hematol; 2005 Jan; 53(1):25-34. PubMed ID: 15607933
[TBL] [Abstract][Full Text] [Related]
20. The influence of three newly synthesized pyrimidine-containing compounds on micronucleus induction and tumor growth.
Nersesyan A; Muradyan R; Arsenyan F
J BUON; 2007; 12(4):521-7. PubMed ID: 18067211
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
